contribute to injury and disease. Based on reports of biliary damage in NAFLD, we hypothesized the involvement of cholangiocyte lipoapoptosis as a mechanism of cellular injury. Here, we demonstrate that the saturated free fatty acids palmitate and stearate induced robust and rapid cell death in cholangiocytes. Palmitate and stearate induced cholangiocyte lipoapoptosis in a concentration-dependent manner in multiple cholangiocyte-derived cell lines. The mechanism of lipoapoptosis relied on the activation of caspase 3/7 activity. There was also a significant up regulation of the proapoptotic BH3-containing protein, PUMA. In addition, palmitate-induced cholangiocyte lipoapoptosis involved a time-dependent increase in the nuclear localization of FoxO3.
We show evidence for post-translational modification of FoxO3, including early (6 h) deacetylation and dephosphorylation that coincide with localization of FoxO3 in the nuclear compartment. By 16 h, nuclear FoxO3 is both phosphorylated and acetylated.
Interestingly, cultured cholangiocyte-derived cells did not accumulate appreciable amounts of neutral lipid upon free fatty acid treatment. In conclusion, our data show that the saturated free fatty acids palmitate and stearate induce cholangiocyte lipoapoptosis via caspase activation, nuclear translocation of FoxO3 and increased proapoptotic PUMA expression. These results suggest that cholangiocyte injury may occur through lipoapoptosis in NAFLD and NASH patients.
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome (1) . NAFLD is a spectrum of liver disease including simple steatosis, nonalcoholic steatohepatitis (NASH), advanced hepatic fibrosis, liver cirrhosis, and hepatocellular carcinoma (1) . NAFLD is the most common liver disease among western countries and it is highly associated with obesity, diabetes, dyslipidemia and hypertension (1) . Recently, a cholestatic presentation of NAFLD with ductular inflammation, bile duct loss and swelling, and bile duct proliferation was reported (2) .
They also showed that bridging fibrosis or cirrhosis was more common in patients with biliary injury (2) . This suggests the involvement of biliary epithelial cell injury as a possible contributor to the severity of NAFLD or NASH (2, 3) . Bile duct epithelial cell expansion, termed the ductular reaction, is a response to injury and has been observed in NAFLD (3) . For instance, staining for keratin 19, a biliary epithelial cell marker, was increased in the liver of NAFLD patients containing portal inflammation and advanced fibrosis (3) . Furthermore, the increased number of bile ducts in NAFLD with stage 4 fibrosis was due to the proliferation of hepatic bipotential progenitor cells (3) . Injured biliary ductular cells produced higher levels of monocyte chemoattractant protein (MCP-1) (3, 4) , and increased MCP-1 has been well documented to attract extracellular-matrix producing cells, such as activated myofibroblasts and hepatic stellate cells to the portal traid (3, 4) .
NAFLD patients have elevated concentrations of circulating saturated free fatty acids (FFAs). FFA-induced hepatocyte lipoapoptosis is a recognized hallmark of NAFLD and includes the activation of c-Jun N-terminal kinase (JNK), mitogen activated protein kinase (MAPK) and extracellular signal-regulated kinase (ERK) (5) . FFAs have also been shown to induce apoptosis in other cell types like cardiomyocytes (6) , and pancreatic β-cells (7). While, hepatocyte lipoapoptosis due to FFAs has been established and implicated in the pathogenesis of NAFLD or NASH (5, 8, 9) , the occurrence of cholangiocyte lipoapoptosis due to FFAs has not been thoroughly tested.
The present study explores cholangiocyte lipoapoptosis using cholangiocyte cell culture models. The data are consistent with saturated FFA-induced cholangiocyte lipoapoptosis via activation of the forkhead family of transcription factor member, FoxO3 and upregulation of the proapoptotic BH3-containing protein PUMA.
EXPERIMENTAL PROCEDURES

Materials
Palmitic acid (#P5585), stearic acid (#S4751), oleic acid (#O1008) and fatty acidfree bovine serum albumin (BSA); (#A3803) were obtained from Sigma-Aldrich. The pan-caspase inhibitor Z-VAD-fmk was from Santa Cruz (#sc3067) and the JNK inhibitor SP600125 (#420119) was from Calbiochem. Magnetic protein G beads (#S1430S) were purchased from New England Bio Labs.
Antibodies
Rabbit antisera against phospho-FoxO3 (Thr32) (#9464), acetylated-lysine (#9441), FoxO3 (#2497), FoxO1 (#2880), phospho-p38-MAPK (#9211), MAPK (#9212), phospho-ERK1/2 (#9101), ERK1/2, phospho-JNK (#9251), and JNK (#9252) were from Cell Signaling. Rabbit antiserum against PUMA (#ab54288) was from Abcam. Goat antiLamin B (#sc-6216) and rabbit anti-actin (#sc-1615) were purchased from Santa Cruz Biotechnology, Inc. Peroxidase-conjugated secondary antibodies were obtained from Jackson Immuno Research lab.
Cell lines and treatment
H69, a human immortalized cholangiocyte cell line, was grown in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and penicillin-streptomycin (100 U/ml), insulin (5 µg/ml), adenine (24.3 µg/ml), epinephrine (1 ug/ml), tri-iodothyronine (T3)-transferrin (T), [T3-2.23 ng/ml, T-8.19 µg/ml], epidermal growth factor (9.9 ng/ml) and hydrocortisone (5.34 µg/ml). KMCH, MzChA-1 and HuCCT-1, human cholangiocarcinoma cell lines, were grown in DMEM supplemented with 10% FBS, penicillin-streptomycin (100 U/ml), insulin (0.5 µg/ml) and G418 (50 µg/ml). BDEneu cells were a kind gift from Dr. Alphonse Sirica (Virginia Commonwealth Univerisity) and were grown in DMEM supplemented with 10% FBS, penicillin-streptomycin (100 U/ml), human transferrin (5 µg/ml), and insulin (0.5 µg/ml) as described (10) . H69, KMCH, HuCCT-1, Mz-ChA-1, and BDEneu cells were treated with the indicated concentrations of FFAs (400-800 µM) dissolved fresh in isopropanol and added to media containing 1% fatty acid-free BSA for 24 h. Vehicle treatment was isopropanol with final concentration of <1% in the medium.
Measurement of apoptosis
Percent apoptosis was quantified by characteristic nuclear morphology and visualized by treatment with the fluorescent DNA-binding dye, DAPI (4', 6-diamidine-2'-phenylindole dihydrochloride) as described before (8) . Briefly, cells were stained with 5 µg/ml of DAPI for 20-30 min at 37°C. Apoptotic nuclei (condensed, fragmented) were counted and presented as a percent of total nuclei. At least 100 cells were counted per well and experiments were performed in triplicate. Caspase 3/7 activity was measured by enzymatic fluorophore release (Apo-One) according to the manufacturer's instructions (Promega) with experiments performed in quadruplicate.
Oil red O staining
Intracellular lipid droplets were stained using oil red O dye as previously described (11) . Briefly, cells were treated with 600 µM of the indicated free fatty acids for 24 h. Cells were washed with PBS and fixed with 10% buffered formalin for 10 min.
Oil red O (2 mg/ml) staining solution was added for 15 min, and washed with water.
Cells were mounted using Fluoromount G (Electron Microscopy Services). Images were obtained by Olympus 1X71 fluorescent microscopy using the rhodamine channel.
Immunoblot and immunofluorescence
Cell lysates containing 25-30 µg of protein were resolved by SDS-PAGE.
Proteins were transferred to a nitrocellulose membrane and visualized by immunoblotting. Mz-ChA-1 cells were labeled with anti-FoxO3 antibody and visualized by alexafluor 488 secondary staining.
Nuclear isolation
Cells were rinsed once with ice cold PBS, then scraped in a buffer containing 10 mM 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid, (HEPES), pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM DTT and 0.5% nonidet-P40 substitute (Sigma) along with the addition of complete protease inhibitor (Roche). Lysates were centrifuged at 15,000 x g for 3 minutes to pellet nuclei. Pellets were suspended in buffer containing 20 mM HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 0.05 mM DTT, 10 % glycerol and protease inhibitor cocktail and incubated for 40 minutes on ice with occasional vigorous vortexing.
Extracts were centrifuged a final time at 15,000 x g and probed for FoxO transcription factors.
Statistics
Statistical analysis was performed using one-way analysis of variance (ANOVA) with bonferroni post hoc correction, unless indicated otherwise.
RESULTS
FFAs induced cholangiocyte lipoapoptosis
Biochemical characteristics of apoptosis include nuclear morphology changes and activation of the caspase cascade. We tested the effect of 400, 600, and 800 µM FFAs on cholangiocyte lipoapoptosis. These concentrations were chosen based on circulating levels of total FFAs found in NAFLD or NASH patients (12, 13) and previous studies (5, 8) . The saturated FFAs palmitate (PA) and stearate (SA) induced cholangiocytes to undergo lipoapoptosis in a concentration-dependent manner. (Fig 1) .
Both PA and SA resulted in 25% -60% apoptosis in H69 cells (Fig 1A) . The monounsaturated fatty acid, oleate (OA) showed no apoptosis at 400 µM and 600 µM.
In contrast, 800 µM of OA-treated H69 cells showed minimal apoptosis compared with 800 µM of PA-or SA-treated cells. To confirm the apoptotic nuclear changes, we tested the activation of caspase 3/7 in FFA-treated cells. PA and SA treatment of cholangiocytes resulted in significantly increased caspase 3/7 activity in a concentration-dependent manner. Indeed, 600 µM and 800 µM PA resulted in 4-and 6-fold increased caspase 3/7 activity in H69 cells, whereas 600 µM and 800 µM SA resulted in 5-and 8-fold increased caspase 3/7 activity, respectively ( Fig 1A) . H69 cells, upon OA treatment again showed a significant increase in caspase activity only at 800 µM OA (Fig 1A) . FFA-induced cholangiocyte lipoapoptosis was then tested in additional cholangiocyte-derived cell lines. PA induced an increase in the number of apoptotic nuclei in KMCH cells at 600 µM and 800 µM, whereas SA induced increased lipoapoptosis starting from 400 µM to 800 µM. Increased caspase activity was observed with increasing concentrations of both PA and SA in KMCH cells (Fig 1B) . Treatment of KMCH cells with OA did not induce apoptosis (Fig 1B) . Both Mz-ChA-1 and HuCCT cell lines showed similar FFA-induced apoptosis with increasing concentrations of PA and SA, but not with OA (Fig 1C & D) . Together, these results suggest that saturated FFAs SA and PA induced cholangiocyte lipoapoptosis.
Caspase-dependent cholangiocyte lipoapoptosis
Since caspase activation was observed in FFA-induced cholangiocyte cell death, we tested whether inhibition of caspases using a cell permeable, pan-caspase inhibitor Z-VAD-fmk, would prevent FFA-induced cell death. In KMCH cells, addition of Z-VADfmk (50 µM) resulted in complete prevention of caspase 3/7 activity induced by PA and SA treatments (Fig 2A) . In parallel, addition of the caspase inhibitor to PA-or SA-treated cells resulted in a significantly decreased percentage of apoptotic nuclei (Fig 2B) . In Mz-ChA-1 cells, Z-VAD-fmk treatment also dramatically reduced PA-or SA-induced cell death (Fig 2C) . Z-VAD-fmk was also protective against lipoapoptosis in H69 and HuCCT cells (Fig 2D and 2E) .
To check the generality of cholangiocyte lipoapoptosis across species, we tested BDEneu cells, an immortalized tumorigenic rat cholangiocyte which has constitutive overexpression of the rat neu/her2 oncogene (10) . BDEneu cells treated with vehicle showed 2.39 ± 0.8 percent apoptotic nuclei and 600 µM PA resulted in significantly increased levels of apoptotic nuclei to 35 ± 2.2 percent (Fig 3A) . Treatment with caspase inhibitor plus PA significantly decreased the percentage of apoptotic nuclei to 16 ± 0.7. In addition, BDEneu cells treated with 600 µM PA showed a 2.5-fold increase in caspase 3/7 activity, which was blocked by Z-VAD-fmk (Fig 3B) .
FFAs induced JNK, ERK1/2 and p38-MAPK activation
Activation of JNK in patients with NAFLD (14) and JNK-dependent hepatocyte lipoapoptosis has been well documented (5, 8) . Here we tested whether activation of JNK was also involved in cholangiocyte lipoapoptosis. Indeed, JNK is activated by phosphorylation after 1 h of PA treatment as compared to vehicle-treated KMCH cells.
Phospho-JNK levels stayed elevated up to 16 h of PA treatment, with peak activation observed at 8 h of PA (Fig 4A) . Similar to JNK activation, PA treatment also resulted in activation of ERK and p38-MAPK via phosphorylation. KMCH cells have some constitutively phosphorylated ERK, as seen in vehicle-treated cells, and 2 h of PA treatment resulted in further activation of ERK. The increase in phospho-ERK levels with PA was time-dependent with peak activation time between 4-8 h (Fig 4A) .
Increased levels of phospho-p38-MAPK were apparent after 1 h of PA and remained elevated until after 24 h of PA treatment (Fig 4A) . PA-induced activation of JNK, ERK and p38-MAPK were also evident in another cholangiocyte, Mz-ChA-1 cells. Here, PAtreated cells showed activation of JNK after 1.5 h of treatment as compared with vehicle-treated cells and phospho-JNK levels returned to basal levels after 3 h of PA treatment (Fig 4B) . Phospho-ERK and phospho-p38-MAPK levels were also increased after 1.5 h of PA treatment and stayed elevated until after 6 h in PA-treated cells. The increased levels of phospho-JNK, phospho-ERK and phospho-p38-MAPK returned to control levels after 8 h of PA treatment in Mz-ChA-1 cells (Fig 4B) . JNK was the main MAPK identified to contribute to hepatocyte lipoapoptosis (5). We next tested the small molecule inhibitor for JNK, SP600125, to see whether PA-induced cholangiocyte lipoapoptosis is JNK dependent. Inhibition of JNK did not alter cholangiocyte lipoapoptosis caused by PA in KMCH cells (Fig 4C) . Inhibition of JNK was confirmed by the loss of phospho-JNK levels with 50 µM of SP600125 treatment (data not shown).
These results suggest that FFAs induced activation of stress kinases JNK, ERK and p38-MAPK and that inhibition of JNK did not alter cholangiocyte lipoapoptosis.
Palmitate induced FoxO3 nuclear localization
We next tested whether FoxO transcription factors (FoxO1 and FoxO3) were (Fig 5A) . Nuclear levels of FoxO3 were also increased in H69 and Mz-ChA-1 cells treated with PA for 16 h (Fig 5B) . FoxO1 expression in the nuclear extracts was high in H69 cells. However, FoxO1 levels were not altered with PA treatment in either H69 or Mz-ChA-1 cells (Fig 5B) . To further confirm nuclear localization, we performed immunofluorescent analysis for FoxO3 in Mz-ChA-1 cells. FoxO3 is clearly localized to the nucleus after 16 h of PA treatment as compared to the cytosolic staining observed in vehicle-treated cells (Fig 5C) . Quantitation of nuclear FoxO3 levels showed a 7-fold increase after 16 h of PA treatment relative to vehicle-treated cells (Fig 5D) . In addition to the increased levels of nuclear FoxO3, a slight change in migration of FoxO3 was noted on SDS-PAGE compared to vehicle-treated cells in both H69 and Mz-ChA-1 cells (Fig 5B) . This altered migration pattern led us to test the post translational modifications like acetylation and phosphorylation in nuclear extracts from KMCH cells treated with PA. FoxO3 was immunoprecipitated from nuclear extracts and probed using an antiacetyl-lysine antibody. We observed a dramatic decrease in levels of acetylated FoxO3 (Fig 5E) . Note there is no obvious increase in total nuclear FoxO3 in this pull-down experiment; this is likely a technical issue, as Immunoprecipitation is not the most suitable method to detect an increase in total FoxO3 (c.f. Fig 5A) . At the same time, FoxO3 was also observed to be un-phosphorylated (Fig 5E) . At a later time point, PA treatment of HuCCT and H69 cells resulted in an increase in the levels of acetylated FoxO3 and phosphorylated FoxO3 (Fig 5F) . These results suggest that FoxO3 was deacetylated and dephosphorylated at early time points, when it first translocated to the nucleus, and at the later time points, FoxO3 is getting modified via acetylation and phosphorylation.
Palmitate increases PUMA protein expression in cholangiocytes
PUMA is a downstream target of FoxO3 (15), thus we assessed the expression of PUMA protein in KMCH cells at various time points after treatment with 800 µM PA.
PA-treated KMCH cells showed elevated levels of PUMA after 2 h as compared to 0 h treated cells and the increased PUMA levels were sustained even after 48 h (Fig 6) . (21) . In the present study, we report lipotoxicity due to saturated FFAs in biliary epithelial cells. This is a caspase-dependent process, consistent with previous studies in other cell types. The monounsaturated fatty acid, OA, showed slight toxicity at the highest concentration. This agrees with a previous study in which OA-induced lipotoxicity in renal proximal tubule cells (22) . Treatment with a pan-caspase inhibitor protected against cholangiocyte lipoapoptosis caused by saturated FFAs. Biliary injury has been reported in a subset of patients with NAFLD compared to a population with similar steatosis (2, 3) . Our data suggest that in patients with metabolic syndrome, higher circulating FFAs may contribute to biliary tree damage.
Cholangiocytes do not develop steatosis with FFA treatment
Further studies will be needed to determine if cholangiocyte lipoapoptosis contributes to the progression of disease from simple steatosis to NASH to liver fibrosis, at least in a subset of patients.
JNK is one of the major cellular stress signaling kinases that is activated during FFA-induced apoptosis. In particular, hepatocyte lipoapoptosis is dependent on JNK activation (5, 8) . However, we found that inhibition of JNK using a small molecule inhibitor did not prevent cholangiocyte lipoapoptosis, suggesting a mechanism of apoptosis beyond JNK activation. A recent study in pancreatic β-cells showed that FFAinduced JNK activation is not critical for apoptosis; but JNK activation was involved in mediating ER-stress signaling pathways (7) . Several studies have also demonstrated that p38-MAPK and ERK can also induce apoptosis in pancreatic β-cells (23, 24) , but the activation of p38-MAPK and ERK has been shown not to be critical for FFA-induced hepatocyte lipoapoptosis (5).
Since JNK was not a critical mediator of FFA-induced cholangiocyte lipoapoptosis, our focus was next on FoxO3. FoxO3, a forkhead family transcription factor, has been shown to activate cell death pathways by inducing the expression of proapoptotic proteins such as PUMA, Bim, p27, and TRAIL (6, 15) . Several studies have confirmed that FoxO3 has direct transcriptional activity on the PUMA promoter and induces the expression of PUMA protein (15, 25) . Increased PUMA can also induce Bax and Bak oligomerization, which further results in activating mitochondrial intrinsic pathways of apoptosis by releasing cytochrome c resulting in caspase activation (26) .
FoxO3 can also be regulated by the Akt signaling pathway, protein phosphatases, and protein deacetylases (Sirt1) (27) (28) (29) . Phosphorylation and acetylation of FoxO3 have been shown to alter the cell death pathways towards cell survival by promoting export of FoxO3 from the nucleus to the cytoplasm (27) . Sirt1 interacts with FoxO3 in the nucleus resulting in deacetylation and altered transcriptional activity (30) . In the present study, deacetylation and dephosphorylation of FoxO3 were observed at the early time points after PA treatment in KMCH cells. After 16 h of PA treatment, the levels of acetylated FoxO3 and phosphorylated FoxO3 were increased. Although phosphorylation has been reported to promote nuclear export, we observed increased nuclear localization of FoxO3 even after 16h of PA. We conclude that in PA-treated cholangiocytes, phosphorylation of FoxO3 at Thr32 is not sufficient to cause nuclear export and FoxO3 inactivation. Previously, PA has been shown to decrease the expression of Sirt1 in pancreatic β-cells (31) and cardiomyocytes (20) . Overexpression of Sirt1 has been shown to protect against FFA-induced pancreatic β-cell apoptosis (32) . Consistently, acetylated FoxO1 has been shown to induce Bim expression and promote apoptosis (33) . FFAs have been shown to induce the expression of miR-195 and miR-34a in cardiomyocytes and pancreatic β-cells, respectively, and both miR-195 and miR-34a have been shown to target Sirt1, resulting in an increase in the acetylated form of transcription factors (34) . At present, we cannot exclude the possibility of microRNA regulation of FFA-induced cholangiocyte lipoapoptosis, which merits our future investigation.
As noted, PUMA is important in lipoapoptosis, and is a downstream target of FoxO3 (15) . Expression of PUMA was found to be up-regulated in human liver biopsies taken from NASH patients as compared to control subjects (8) . In our experiments, PUMA expression was up regulated by FFAs in cholangiocytes. Our time-course of PUMA expression revealed a rapid increase in PUMA protein that is sustained through 48 h. Because of the rapid induction, it is likely the early increase is due, in part, to posttranscriptional mechanisms. The sustained increase in expression may be the result of (A) BDEneu cells were treated with 600 µM palmitate (PA) or PA plus 50 µM caspase inhibitor, Z-VAD-fmk (ZVAD) for 24 h. Vehicle for PA was isopropanol (Veh' <1% final) and control for Z-VAD-fmk was DMSO (<1% final). Apoptotic nuclei were counted and expressed as a percent of total nuclei, at least 100 cells per replicate were counted. (B) BDEneu cells were treated in parallel as above for 24 h, followed by quantitation of caspase 3/7 activity, and results are expressed as fold-change over isopropanol-treated cells (Veh). Each value represents the mean ± SEM of separate experiments (n = 6). *p<0.001, compared to vehicle treated cells and #p<0.001 compared to PA-treated cells. 
